Synthetic Biologics, Inc. (NYSE: SYN) is developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. The company’s pipeline includes a range of oral drugs, biologics and antibiotics designed to that target a range of indications to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), prevent Clostridium difficile (C. difficile) infection, treat Pertussis and Acinetobacter infections, prevent and treat a root cause of a subset of IBS, or to treat relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.  For more information, visit the company’s website at www.syntheticbiologics.com